Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: GlobeNewswire
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. “We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence in patient care,” said Marcio Souza, president and chief executive officer of Praxis. Ms. DeSimone served as president of U.S. Oncology at Merck & Co., Inc. from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as interim president of U.S. Pharma to help navigate
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Participate in Upcoming April Conferences [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 3/5/24 - Beat
PRAX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 3/29/24 - Form 8-K
- PRAX's page on the SEC website